Dr. Reddy's launches Penicillamine Capsules in US market

28 Aug 2020 Evaluate

Dr. Reddy's Laboratories has launched Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) Capsules, 250 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Cuprimine brand and generic market had U.S. sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health. The company’s Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1246.25 -20.90 (-1.65%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×